Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen for Allo-HSCT

Sponsor
First Affiliated Hospital of Zhejiang University
Study ID
NCT05084027
Phase
PHASE2
Status
Unknown

Conditions

  • Allogeneic Hematopoietic Stem Cell Transplantation
  • Hematologic Malignancy
  • Older Patients

Eligibility Criteria

Sex
ALL
Age
50 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

venetoclax combining with fludarabine and melphalan as conditioning regimen prior to allogeneic hematopoietic stem cell transplantation for older patients with hematologic malignancies

Key Dates

Start date
Oct 7, 2021
Status verified
Oct 2021
Primary completion
Sep 30, 2022
Completion
Sep 30, 2024

Study Design

Enrollment
50 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: treatment group
    older patients accepting venetoclax combining with fludarabine and melphalan as conditioning regimen prior to allogeneic hematopoietic stem cell transplantation treatment

Primary Outcome Measure

disease free survival [ Time Frame: 2 year ]

Central Contacts

Related Studies